Iovance wins with Amtagvi and the ADC train chugs on
Podcast: BioSpacePublished On: Wed Feb 21 2024
Description: This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.
The note was deleted
The note was saved
Your message was sent